Hematology/Oncology Fellowships

Contact Us

617-632-3474

Kim Bremner
Fellowship Coordinator
Fax: 617-632-2260

EMAIL

Dana-Farber Cancer Institute, in collaboration with Mass General Brigham and Boston Children’s Hospital, offers two fellowship programs in hematology/oncology that provide clinical training and basic research training for MDs or MD/PhDs:

  • Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
    • Hematology/Oncology Track
    • Classical Hematology Track
  • Pediatric Hematology/Oncology Training Program

Dana-Farber/Mass General Brigham Fellowship in Adult Hematology/Oncology and Classical Hematology

The Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology prepares academically oriented physicians to become leaders in clinical and laboratory investigation, clinical care, and education.

The program has two interconnected tracks – a Hematology/Oncology Track that admits 14 new fellows each year, and a Classical Hematology Track that admits 2 new fellows each year. After an initial year of intensive clinical training, fellows in both tracks pursue two or more years of in-depth clinical, translational, and/or basic science research.

    During the first year of training, fellows in both the Hematology/Oncology Track and the Classical Hematology Track divide their time among the Dana-Farber, Massachusetts General Hospital (MGH), and Brigham and Women's Hospital (BWH) campuses. The combined institutions have more than 1,400 inpatient beds, and provide inpatient and ambulatory hematology and oncology care to patients from around the world.

    Hematology/Oncology Track: During the clinical year, outpatient hematology and oncology experiences are organized around disease-specific programs, and fellows are supervised directly by faculty mentors in each clinical division. Fellows working in inpatient services provide care and consultative services in hematology and medical oncology to a varied population of patients. Trainees also attend a wide variety of teaching conferences at both the Longwood (Dana-Farber and BWH) and MGH campuses. In addition, there are weekly disease-oriented teaching sessions sponsored by the relevant programs.

    Classical Hematology Track: The Classical Hematology track is a new addition to the Dana-Farber/Mass General Brigham Fellowship program. Interested applicants can begin submitting applications for the Classical Hematology Track in July 2022. The goal of the Classical Hematology Track is to prepare physicians for both clinical and research careers in classical hematology. During the clinical year, outpatient malignant and non-malignant hematology experiences will be organized around disease-specific programs, and fellows will be supervised directly by faculty mentors in each clinical division. Fellows working in inpatient services will provide care and consultative services in malignant and non-malignant hematology to a varied population of patients. Trainees will also attend a wide variety of teaching conferences at both the Longwood (Dana-Farber and BWH) and MGH campuses. Conferences will include joint conferences with the fellows in the Hematology/Oncology Track and conferences designed specifically for the Classical Hematology fellows.

    In the second year and beyond, fellows in both the Hematology/Oncology Track and the Classical Hematology Track begin a period of immersive research, with the aim of assuming independent research programs in respected academic institutions.

    A variety of investigative opportunities, ranging from the most fundamental molecular biology to clinical trials and health outcome analyses, are available at Dana-Farber, Brigham and Women's Hospital, and MGH, as well as in laboratories located at the MGH Cancer Center in Charlestown, the Harvard Medical School, Boston Children's Hospital, and the Broad Institute of MIT and Harvard. Additional clinical training is available for those in the Hematology/Oncology Track desiring to board in hematology. Additionally, upper-level fellows maintain a longitudinal continuity clinic in the disease center and campus of their choosing.

    Amin Aalipour, MD, PhD

    Dr. Amin Aalipour is originally from San Diego, CA. He earned a BS in Materials Science & Engineering and MS in Management Science & Engineering from Stanford University. He subsequently joined Stanford’s Medical Scientist Training Program to obtain his MD and PhD. He completed residency in Internal Medicine at Brigham and Women’s Hospital.

    Brandon Aubrey, MBBS, PhD

    Dr. Brandon Aubrey is originally from Sydney, Australia. He obtained his BA in Biochemistry and Biophysics at the University of Pennsylvania, MBBS degree at the University of Sydney and PhD from the University of Melbourne. Brandon previously completed medical training in Australia to become a certified clinical hematologist and pathologist with dual fellowships from the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia.

    Robert Dilley, MD, PhD

    Robert was born in Los Angeles and grew up in Atlanta and then Philadelphia. He obtained a BS in Molecular and Cellular Biology at Johns Hopkins University, followed by an MD and PhD in Cell and Molecular Biology at the University of Pennsylvania. He completed his internal medicine residency at Massachusetts General Hospital in the Stanbury Physician Scientist Program.

    Richard Ebright, MD, PhD

    Dr. Richard Ebright is originally from North Brunswick, NJ. He obtained his BA in Chemical and Physical Biology at Harvard College and a combined MD/PhD from Harvard Medical School. He completed his internal medicine residency at MGH. For his MD/PhD, Richard worked with Daniel Haber and Shyamala Maheswaran at the MGH Cancer Center, studying genes that promote the metastatic capacity of circulating tumor cells.

    Jeremy Grevet, MD, PhD

    Dr. Jeremy Grevet is originally from Paris, France and grew up spending his summers visiting his mother’s side of the family in Madison, WI. He has dual American/French citizenship. He obtained his BA in Mathematics and Chemistry from Carleton College and a combined MD/PhD from the Perelman School of Medicine at the University of Pennsylvania.

    Gunsagar S. Gulati, MD, PhD

    Gunsagar is originally from Boulder, CO. He obtained his BA in Human Developmental and Regenerative Biology at Harvard College and a combined MD/PhD in Cancer Biology from Stanford University School of Medicine. He completed his internal medicine residency at Brigham and Women’s Hospital. He is interested in understanding the transcriptional programs in tumor cells that drive cancer growth, therapy resistance, and distant metastasis in patients.

    Joanne I. Hsu, MD PhD

    Joanne grew up in a small town close by Vancouver, WA. She obtained her BS in Neurobiology at the University of Washington, and a combined MD and PhD from Baylor College of Medicine in Houston, TX. She conducted her thesis work in Margaret (Peggy) Goodell’s laboratory, where she studied hematopoietic stem cells and the impact of chemotherapy on the evolutionary selection of premalignant clones in the blood.

    H. Moses Murdock, MD

    Dr. Moses Murdock is originally from Orlando, FL. He obtained his BS in Molecular Biology and Microbiology at the University of Central Florida and MD from the Perelman School of Medicine at the University of Pennsylvania. He completed his internal medicine residency at Brigham and Women’s Hospital. Prior to medical school, he served as a post-baccalaureate intramural research training associate at the National Institutes of Health/National Institute of Allergy and Infectious Diseases studying primary immunodeficiencies.

    Ashley Odai-Afotey, MD

    Dr. Ashley Odai-Afotey is originally from Olney/Silver Spring, MD. She obtained her BA in Biological Sciences with a concentration in molecular biology at Cornell University, graduating summa cum laude. She then went on to obtain her MD from Yale School of Medicine. She completed her internal medicine residency at Brigham and Women’s Hospital. Prior to medical school, she worked at N Street Village as an HIV Heath Specialist via the Washington AIDS Partnership AmeriCorps Program, where she led various health educational classes and connected women with shelter resources.

    Tess O'Meara, MD

    Dr. Tess O’Meara grew up in Dallas, TX, before attending college at Princeton University. At Princeton, she majored in Molecular Biology with minors in Neuroscience and Portuguese Language and Culture. She then spent one year working at the Breast Cancer Center at the University of California, San Francisco, before coming back to the East coast for medical school at Yale School of Medicine. She completed her Internal Medicine residency at Brigham and Women’s Hospital.

    Miriam Osei, MD, MPH

    Dr. Miriam Osei was born and lived in Accra, Ghana until the age of thirteen, when she emigrated to Dallas, Texas. She obtained both her BA in Biochemistry and her MD at Columbia University. She completed her combined internal medicine and global health equity residency at Brigham & Women's Hospital. While in residency, she also obtained her MPH in epidemiology and biostatistics at the Harvard T.H. Chan School of Public Health.

    Hari S. Raman, MD, MBA

    Dr. Hari Raman is originally from Dallas, TX. He obtained his BS in Biomedical Engineering at Columbia University, an MD from Washington University School of Medicine, and an MBA from Harvard Business School. He completed his internal medicine residency at Brigham and Women’s Hospital. Prior to medical school, he served as an analyst for IMS Consulting Group, where he provided management and strategy consulting for major pharmaceutical firms and biotechnology companies.

    David Reshef, MD, PhD

    Dr. David Reshef grew up between Jerusalem, Kenya, and Maryland. He completed a BS and MEng in computer science at MIT and a combined MD/PhD from Harvard Medical School and MIT. He completed his internal medicine residency at Brigham and Women’s Hospital. Prior to medical school, he was a Marshall Scholar in the Department of Statistics at the University of Oxford. He then attended the Harvard-MIT Health Sciences & Technology (HST) MD-PhD program.

    Andrew B. Song, MD

    Andrew is originally from Chicago, IL. He obtained his BA in Biological Sciences at the University of Chicago and his MD at Harvard Medical School. He completed an Internal Medicine residency at Massachusetts General Hospital. At MGH, Andrew developed a career interest in classical hematology and clinical investigation, with a focus on platelet disorders and thrombosis/hemostasis.

    Sarah Waliany, MD, MS

    Dr. Sarah Waliany is from Los Angeles, CA. She obtained her BS in Biological Sciences at the University of Southern California, and received her MD and MS in Epidemiology and Clinical Research at Stanford University School of Medicine. She completed her internal medicine residency at Stanford Health Care where she subsequently also completed a year as a Chief Resident. During medical school and residency at Stanford, Sarah did clinical and translational research in both cardio-oncology and thoracic oncology.

    Mike Wang, MD, MHS

    Dr. Mike Wang was born in Vancouver, British Columbia. He obtained his BS in Microbiology and Biotechnology at the University of Toronto, and a combined MD/Master of Health Sciences from Yale School of Medicine. He completed his internal medicine residency at Massachusetts General Hospital.

    Second Year Fellows 2022

    Daniel Ardeljan, MD, PhD
    Narsis Attar, MD, PhD
    Mary Boulanger, MD
    Jamie O. Brett, MD, PhD
    Allison E.B. Chang, MD, PhD
    Matthew J. Emmett, MD, PhD
    Emma C. Fink, MD, PhD
    Benson M. George, MD, PhD
    Eran Hodis, MD, PhD
    Sara J. Khosrowjerdi, MD
    Lauren Merz, MSc, MD
    Ian A. Roundtree, MD, PhD
    Elliot C. Woods, MD, PhD

    Third Year Fellows 2021

    Jordan M. Chinai, MD, PhD, Fellow DFCI/MGB
    Charles S. Dai, MD, Fellow DFCI/MGB
    Elijah P.B. Darnell, MD, Fellow DFCI/MGB
    Haley Ellis, MD, Fellow DFCI/MGB
    Dan Y. Gui, MD, PhD, Fellow DFCI/MGB
    Alexander C. Jordan, MD, Fellow DFCI/MGB
    Mwanasha H. Merrill, MD, Fellow DFCI/MGB
    Abirami Natarajan, MD, Fellow DFCI/MGB
    Rachel H. Occhiogrosso, MD, Fellow DFCI/MGB
    Leon Pappas, MSc, MD, PhD, Fellow DFCI/MGB
    Nolan Priedigkeit, MD, PhD, Fellow DFCI/MGB
    John C. Schell, MD, PhD, Fellow DFCI/MGB
    Vinayak Venkataraman, MD, Fellow DFCI/MGB - Medical Oncologist, Dana-Farber Cancer Institute
    Jeremiah Wala, MS, MD, PhD, Fellow DFCI/MGB

    2020

    Justin S. Becker, MD, PhD, Fellow DFCI/MGB
    Elliott J. Brea, MD, PhD, Fellow DFCI/MGB
    Elizabeth J. Carstens, MD, Fellow DFCI/MGB
    Jooho Chung, MD, PhD, Fellow DFCI/MGB
    Alissa J. Cooper, MD, Fellow DFCI/MGB
    Brandon M. Huffman, MD, Fellow DFCI/MGB
    Nathalie R. Javidi-Sharifi MD, PhD, Fellow DFCI/MGB
    Janice S. Kim, MD, Fellow DFCI/MGB
    Marla D. Lipsyc-Sharf, MD, Fellow DFCI/MGB
    Asaf Maoz, MD, Fellow DFCI/MGB
    Richard A. Newcomb, MD, Fellow DFCI/MGB
    Erica M. Pimenta, MD, PhD, Fellow DFCI/MGB
    Thomas J. Roberts, MD, MBA, Fellow DFCI/MGB
    Christine E. Ryan, MD, Fellow DFCI/MGB
    Maclean S. Sellers, MD, PhD, Fellow DFCI/MGB
    Rebecca L. Zon, MD, Fellow DFCI/MGB

    2019

    Evan C. Chen, MD, Medical Oncologist at Dana Farber Cancer Institute
    William J. Gibson, MD, PhD, Fellow DFCI/MGB
    Julie E. Haydu, MD, PhD, Medical Oncologist at Massachusetts General Hospital
    Daniel E. Lage, MD, MBA, MSc, Medical Oncologist at Massachusetts General Hospital
    Jaclyn LoPiccolo, MD, PhD, Fellow DFCI/MGB
    Alexandra K. Maurer, MD, PhD, Medical Oncologist at Dana Farber Cancer Institute
    Catherine B. Meador, M, PhD, Medical Oncologist at Massachusetts General Hospital
    Arielle J. Medford, MD, Fellow DFCI/MGB
    Arnav Mehta, MD, PhD, Medical Oncologist at Massachusetts General Hospital
    Vivek Naranbhai, MBCHB, PhD, DPhil, Fellow DFCI/MGB
    Philipp J. Rauch, MD, Medical Oncologist at Dana Farber Cancer Institute
    Aswin Sekar, MD, PhD, Fellow DFCI/MGB
    Eleni Stavrou, MD, Memorial Sloan Kettering Cancer Center
    Matthew R. Strickland, MD, Medical Oncologist at Massachusetts General Hospital

    2018

    Steven M. Blum, MD, Medical Oncologist at Dana-Farber Cancer Institute
    Cynthia K. Hahn, MD, PhD, Fellow DF/MGB
    Chi-Joan How, MD, Medical Oncologist at Dana-Farber Cancer Institute
    P. Connor Johnson, MD, Instructor in Medicine at Massachusetts General Hospital
    Jonathan M.L. Ostrem, MD, PhD, Assistant Professor UCSF
    Jeffrey W. Patterson-Fortin, MD, PhD, Medical Oncologist at Dana-Farber Cancer Institute
    Rishi Puram, MD, PhD, Fellow DF/MGB
    Praful K. Ravi, MBBCh, Medical Oncologist at Dana-Farber Cancer Institute
    Jaime L. Schneider, MD, PhD, Medical Oncologist at Massachusetts General Hospital
    Frederick D. Tsai, MD, PhD, Fellow DF/MGB
    Vivek Upadhyay, MD, Fellow DF/MGB
    Lachelle D. Weeks, MD, PhD, Medical Oncologist at Dana-Farber Cancer Institute
    Kipp A. Weiskopf, MD, PhD, Fellow DF/MGB
    Jordan C. Wengrod, MD, PhD, Fellow DF/MGB

    2017

    Daniel L. Abravanel, MD, PhD, Medical Oncologist at Dana-Farber Cancer Institute
    Sylvan C. Baca, MD, PhD, Medical Oncologist at Dana-Farber Cancer Institute
    Jacob E. Berchuck, MD, Medical Oncologist at Dana-Farber Cancer Institute
    Christopher T. Chen, MD, Medical Oncologist at Dana-Farber Cancer Institute
    Bradley D. Hunter, MD, MPH, Hematology/Oncology Intermountain Medical Group
    Geon Kim, MD, Hematology Attending Massachusetts General Hospital
    Erik K. Knelson, MD, PhD, Clinical Director, Early State Oncology, Merck
    Elizabeth K. Lee, MD, Medical Oncologist at Dana-Farber Cancer Institute
    Mark B. Leick, MD, Medical Oncologist at Massachusetts General Hospital
    Christopher S. Nabel, MD, PhD, Medical Oncologist at Massachusetts General Hospital
    Alexander A. Parent, MD, PhD, Medical Director, Oncology TAU, at Takeda Pharmaceuticals
    Christopher R. Reilly, MD, Medical Oncologist at Dana-Farber Cancer Institute
    James A. Torchia, MD, PhD, Fellow DF/MGB
    Mounica Vallurupalli, MD, Fellow DF/MGB

    All applications for this program are processed through the Electronic Residency Application Service (ERAS). Please note that both tracks are listed under Brigham and Women's Hospital, not Dana-Farber Cancer Institute. Applicants can apply to either one or both tracks.

    The deadline for applications is August 31.

    Pediatric Hematology/Oncology Fellowship Program

    The Pediatric Hematology/Oncology Fellowship Program at Dana-Farber Cancer Institute and Boston Children's Hospital is one of the oldest and most distinguished in the world.

    The program admits six new fellows per year. Fellows spend one year in full-time clinical work and two or more years in research training, depending on previous training and interests.

    The program is geared to broadly train MD or MD/PhD fellows in any of the areas of clinical research, including outcomes, ethics, epidemiology, therapeutic trials, and translational research, or in one of the major basic science disciplines: protein chemistry, structural biology, molecular biology, stem cell and developmental biology, genetics, genomics, immunology, systems biology, neuroscience, or cell biology.

    The breadth and diversity of our patient population, combined with the depth of expertise of our teaching faculty, provides the highest quality clinical training in pediatric hematology and oncology. Our program also offers unparalleled opportunities for research and scholarship, fostering the academic passions of all fellows.

    Learn more about the Pediatric Hematology/Oncology Fellowship Program.

    Hematology/Oncology Fellowship Program

    Learn about the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology.